Evidence map›Paper›PMID 40626669›Full record

ArticlePathologica2025

Homologous recombination deficiency testing in ovarian cancer: the diagnostic experience of a referral Italian institution.

Francesco Pepe, Gianluca Russo, Amedeo Cefaliello, Maria Rosaria Lamia, Roberto Buonaiuto, Giuseppina Crimaldi, Claudia Scimone, Lucia Palumbo, Giuseppina Roscigno, Paola Parente and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Francesco Pepe *Department of Public Health, Federico II University of Naples, Naples, Italy.
Gianluca Russo *Department of Public Health, Federico II University of Naples, Naples, Italy.
Amedeo CefalielloDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Maria Rosaria LamiaDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Roberto BuonaiutoDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Giuseppina CrimaldiDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Claudia ScimoneDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Lucia PalumboDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Giuseppina RoscignoDepartment of Biology, Federico II University of Naples, Italy.
Paola ParentePathology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG).
Maria Chiara De FinisPathology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG).
Fabiola FiordelisiPathology Unit, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG).
Claudia MarchettiDipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy; Dipartimento Scienze della Vita e Sanità Pubblica, Università Cattolica del Sacro Cuore, Rome, Italy.
Pierluigi GiampaolinoDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Carmine De AngelisDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Roberto BiancoDepartment of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
Giancarlo TronconeDepartment of Public Health, Federico II University of Naples, Naples, Italy.
Umberto MalapelleDepartment of Public Health, Federico II University of Naples, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Recently, precision medicine has drastically modified clinical paradigm for the clinical stratification of high-grade serous ovarian cancer (HGSOC) patients. International societies approved poly (ADP-ribose) polymerase (PARP) inhibitors (PARPIs) to treat platinum-sensitive Methods: From May 2023 to Jan 2024 molecular records from 147 HGSOC patients simultaneously tested for Results: Overall, 2 out of 147 (1.3%) cases were morphologically classified as inadequate. Simultaneous Conclusions: HRD testing is a reliable method for the clinical management of HGSOC patients.

Indexed as

Biomarkers, TumorHomologous RecombinationOvarian NeoplasmsRecombinational DNA RepairAdultAgedAged, 80 and overBRCA1 ProteinBRCA2 ProteinFemaleHigh-Throughput Nucleotide SequencingHumansItalyMiddle AgedMutationReferral and ConsultationBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanmolecular pathologyovarian neoplasmspoint of care testing

Identifiers

PMID40626669
PMCPMC12236138

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.